A 2-year Phase 3, Multicenter, Prospective, Randomized, Double-Masked, Parallel-Group Study of EYP-1901, a Tyrosine Kinase Inhibitor (TKI), Compared to Aflibercept in Subjects With Wet AMD
A 2-year Phase 3, Multicenter, Prospective, Randomized, Double-Masked, Parallel-Group Study of EYP-1901, a Tyrosine Kinase Inhibitor (TKI), Compared to Aflibercept in Subjects With Wet AMD
This is a phase 3 randomized, double -masked study comparing the efficacy of EYP-1901 against Aflibercept.
Inclusion Criteria:
Exclusion Criteria:
Mountain View, California 94040, United States
St. Petersburg, Florida 33711, United States